American CyroStem introduces New Stem Cell Processing and Cryogenic Storage Laboratory.
EATONTOWN, NJ – April 6, 2016 — American CryoStem Corporation (OTC Pink: CRYO), a leading developer and marketer of patented adipose tissue-based cellular technologies for the regenerative and personalized medicine industries with laboratories in Tokyo, Hong Kong and Shenzhen, China, today announced that it has expanded with the opening of a new, state-of-the-art lab facility in Princeton, NJ.
The Company has moved from its original lab facility into a new, larger laboratory facility that provides processing and bio-banking of adipose tissue (fat) for cosmetic tissue grafting, Stromal Vascular Fraction (SVF), and culturing of autologous adipose derived mesenchymal stem cells (ADSCs). The new laboratory will support the Company’s increasing processing and bio-banking operations with far higher capacity, at enhanced efficiency to meet growing demand in the US and internationally – in addition to increased R&D capabilities.
John Arnone, Chairman and CEO of American CryoStem Corporation, stated, “Our new, larger Princeton lab contains a suite of advanced biotechnology and stem cell processing equipment. This investment reflects our confidence in the growing global demand we are seeing for our patented technologies and services, as well as the solid progress achieved in our new business initiatives under active development.
“The move into a new, world-class facility is an important company milestone,” Mr. Arnone added. “We’re excited to be in the new lab as we successfully execute on plan to fully commercialize these advanced stem cell technologies — with the promise of helping to revolutionize the regenerative medicine industry.”
Today’s announcement marks the culmination of strong company progress. American CryoStem’s first US laboratory was in a New Jersey-based biotech incubator that provided capital efficiency during its development stage, enabling it to complete its initial stem cell platform, establish its brand in the industry and receive the Incubator Company of the Year award from the NJ Business Incubation Network. There, it established and validated its proprietary protocols, developed world-class Standard Operating Procedures (SOP’s), filed eight US and three international patents and initiated revenue producing services around its adipose tissue collection-processing-expansion-storage platform.
Now, and going forward, this new facility increases storage capacity, shortens turnaround times for processing, provides a robust tech platform for additional research and allows the company ample space to deliver its proprietary consumable products to its growing global footprint of processing laboratories. It is located in the heart of New Jersey’s biotech and pharmaceutical corridor at Princeton Corporate Plaza, 7 Deer Park Drive, Building 7, Suite C7, Monmouth Junction, NJ 08852. For more information please contact email@example.com or call the Company directly at 732-747-1007.
About American CryoStem Corporation
Founded in 2008, American CryoStem Corporation is a biotechnology pioneer, standardizing adipose tissue derived technologies for the fields of regenerative and personalized medicine. The Company has developed Standard Operating Procedures (SOPs) to operate state-of-art, FDA-registered, clinical laboratories dedicated to the collection, processing, bio-banking, culturing and differentiation of autologous adipose tissue (fat) and adipose derived stem cells (ADSCs). Leveraging its Institutional Review Board (IRB) approved platform technologies with a portfolio of developed products, the Company is building a global network of licensed laboratory affiliates and physician networks to deliver current and future cellular applications.
The Company maintains a portfolio of intellectual property that forms the foundation of its standardized platform and products which support a growing pipeline of stem cell applications and biologic products. The Company’s R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC therapies. For additional information, please visit www.americancryostem.com and www.acslaboratories.com.
This press release may contain forward-looking statements, including information about management’s view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.